Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AIM IMMUNOTECH INC.

(AIM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

AIM ImmunoTech : Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy

07/12/2021 | 09:51am EDT

OCALA, Fla. - AIM ImmunoTech Inc. (NYSE American: AIM) announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the company's drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza.

This antiviral study will be conducted by hVIVO, a subsidiary of Open Orphan plc, a rapidly growing specialist pharmaceutical services clinical research organization and world leader in vaccine and antiviral testing using human challenge clinical trials. The trial is expected to commence in Q4 2021.

A successful Phase 2a study could also establish Ampligen as a potential prophylaxis against future viral variants and future novel respiratory viruses for which there are no current therapies, as well as known viruses such as SARS-CoV-2, which causes COVID-19.

In an HCT, subjects are intentionally exposed to particular diseases to test how the diseases will respond to potential therapeutics. An HCT will allow AIM to expedite the development process for Ampligen by ensuring high infection rates for subjects who receive the drug, therefore also ensuring large data sets with potentially statistically significant results.

This Phase 2a study will come in the wake of AIM's recent announcement that all subjects have completed treatment in the company's Phase 1 clinical study to assess the safety, tolerability and biological activity of Ampligen as a potential intranasal therapy. A total of 40 healthy subjects received either Ampligen or a placebo in the trial, with Ampligen given at four escalating dosages across four cohorts, to a maximum level of 1,250 micrograms. The study reported no Severe Adverse Events at any dosage level. A final study report is expect in the third quarter of 2021.

Unlike other drugs tailored to combat specific diseases, Ampligen targets and amplifies the natural immune system pathways that fight viruses, meaning that Ampligen delivered via an intranasal device could be an effective preventive therapy for people who may be exposed to, or have recently been exposed to, a respiratory virus such as influenza, or even common coronaviruses and rhinoviruses (like the common cold). Success against these common viruses could also indicate that an Ampligen prophylaxis could help blunt the spread of infection from lethal coronaviruses, as well as other serious viruses. This Phase 2a study will test this proposition in humans.

AIM CEO Thomas K. Equels, commented: 'It is our belief that Ampligen's mechanism of action regarding the human innate immune system gives Ampligen broad-spectrum capabilities as an antiviral prophylaxis and therapeutic. The ability to do a Human Challenge Trial using hRV and Influenza allows us to test in humans Ampligen's potential role as a powerful prophylaxis and therapeutic for a wide range of respiratory viruses. It is our belief that if it works in these two viruses, then it will have the potential to have a similar impact in other respiratory viruses.'

Cathal Friel, Executive Chairman of Open Orphan, stated: 'We are delighted to commence work with AIM ImmunoTech, a leading immuno-pharma company, to test their product and to demonstrate our expertise in testing vaccines and antivirals using our world-leading portfolio of human challenge models. While the pandemic has undoubtedly inflicted a lot of loss and suffering globally, it has also taught us a valuable lesson in pandemic preparedness. It is my belief therefore that the infectious disease market has been utterly transformed and is going to grow exponentially in the years ahead. Challenge studies are a key weapon in the arsenal against infectious diseases as they can bring effective treatments and vaccines to the market both quicker and faster than they could otherwise.'

An Ampligen prophylaxis could potentially benefit vulnerable populations who are at increased risk of transmission due to their environments, such as hospital workers; people on cruise, cargo or military ships; people on commercial airplanes; and service personnel in close quarters on military installations.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

About Open Orphan plc

Open Orphan plc (London and Euronext: ORPH) is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The company provides services to Big Pharma, biotech and government/public health organizations.

Open Orphan runs challenge studies in London from both its 19-bedroom Whitechapel quarantine clinic, opened in February 2021, and its 24-bedroom QMB clinic which also has a highly specialized virology and immunology laboratory on-site. Open Orphan has a leading portfolio of eight human challenge study models for conditions such as RSV, flu, asthma and COPD. In addition, Open Orphan is also developing the world's first COVID-19 human challenge study model as part of the Human Challenge Program and has signed a reservation contract with the UK Government for the first three COVID-19 vaccine challenge studies.

Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company's Disease in Motion platform, this unique dataset includes clinical, immunological, virological and digital (wearable) biomarkers. The Disease in Motion platform has many potential applications across a wide variety of end users including big technology, wearables, pharma and biotech companies. Following COVID-19 there is now a renewed interest and investment in infectious diseases.

Open Orphan's Paris office has been providing biometry, data management and statistics to its many European pharmaceutical clients for over 20 years. For over 15 years, the Company's Netherlands office has been providing drug development consultancy and services, including CMC (chemistry, manufacturing and controls), PK and medical writing, to a broad range of European clients. Both offices are now also fully integrated with the London office and working on challenge study contracts as well as supporting third party trial contracts.

Cautionary Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the 'PSLRA'). Words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate' and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA. No assurances can be given as to whether any studies will be successful or yield favorable data. Studies and trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. Significant additional testing and trials will be required to determine whether Ampligen will be effective in the treatment of respiratory viruses, including SARS-CoV-2, as an intranasal therapy or otherwise, and no assurance can be given that this will be the case. There is the potential for delays in clinical trial enrollment and reporting because of the COVID-19 medical emergency. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Contact:

Crescendo Communications, LLC

Phone: 212-671-1021

Email: aim@crescendo-ir.com

AIM ImmunoTech Inc

Phone: 800-778-4042

Email: IR@aimimmuno.com

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
AIM IMMUNOTECH INC. -1.95% 2.01 Delayed Quote.14.53%
OPEN ORPHAN PLC -3.87% 21.75 Delayed Quote.-12.31%
All news about AIM IMMUNOTECH INC.
03:04pAIM IMMUNOTECH : Files Preliminary Patent Application For Antiviral Drug Ampligen
MT
09:20aAIM IMMUNOTECH : Files Provisional Patent Application for Ampligen as an Early-Onset Intra..
AQ
09/21AIM IMMUNOTECH INC. : Change in Directors or Principal Officers (form 8-K)
AQ
09/21AIM Immunotech Inc. Announces Retirement of Ellen Lintal as Chief Financial Officer, Ef..
CI
09/21AIM IMMUNOTECH : FDA Meeting Request for Ampligen Study Transferred to Neurology Division;..
MT
09/21AIM IMMUNOTECH : Announces Positive Progress on Requested FDA Meeting for Proposed Amplige..
AQ
09/21AIM Immunotech Announces Positive Progress on Requested FDA Meeting for Proposed Amplig..
CI
09/20AIM IMMUNOTECH : Provides an Update on Its Pending Phase 2a Human Challenge Trial Using it..
AQ
09/20AIM ImmunoTech Inc. Provides Status Update on its Pending Phase 2A Human Challenge Tria..
CI
09/17AIM IMMUNOTECH : Company Presentation - September 2021
PU
More news
Financials (USD)
Sales 2021 0,13 M - -
Net income 2021 -17,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,54x
Yield 2021 -
Capitalization 98,1 M 98,1 M -
Capi. / Sales 2021 760x
Capi. / Sales 2022 363x
Nbr of Employees 22
Free-Float 98,8%
Chart AIM IMMUNOTECH INC.
Duration : Period :
AIM ImmunoTech Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AIM IMMUNOTECH INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 2,05 $
Average target price 6,67 $
Spread / Average Target 225%
EPS Revisions
Managers and Directors
Thomas Kenwood Equels Executive Vice Chairman, President & CEO
Ellen M. Lintal Chief Financial Officer
William M. Mitchell Chairman
David R. Strayer Chief Scientific & Medical Officer
Peter W. Rodino COO, Secretary & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
AIM IMMUNOTECH INC.14.53%98
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
REGENERON PHARMACEUTICALS32.25%66 425
WUXI APPTEC CO., LTD.35.04%59 817
VERTEX PHARMACEUTICALS-22.31%47 634